Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells

Fang,Zhiqing; Xu,Xiulian; Zhou,Zunlin; Xu,Zhonghua; Liu,Zhaoxu

doi:10.3892/mmr.2014.2097

Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells

Authors:
- Zhiqing Fang
- Xiulian Xu
- Zunlin Zhou
- Zhonghua Xu
- Zhaoxu Liu
View Affiliations

Affiliations: Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Surgery Department, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: March 31, 2014 https://doi.org/10.3892/mmr.2014.2097
Pages: 2251-2256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that metformin (Met) may reduce the risk of cancer development. In the present study, the anti‑cancer effects of Met in A498 cells were investigated. It was found that Met inhibited A498 cell proliferation in a time‑ and dose‑dependent manner, as well as induced the activation of AMP‑activated protein kinase. It was also demonstrated that Met promoted A498 cell apoptosis and mechanistic studies suggested that this was mediated by the downregulation of B‑cell lymphoma 2 and concurrent upregulation of Bcl‑2‑associated X protein. In addition, it was observed that Met induced G1 cell cycle arrest by decreasing cyclin D1 expression. Furthermore, the results demonstrated that Met reduced A498 cell migration and invasion in vitro by decreasing matrix metalloproteinase‑2, which indicated its potential to inhibit renal cancer metastasis. In combination, these results provide evidence that Met is important in anti‑renal cancer therapy, and thus may serve as a novel and efficient agent for renal cancer treatment.

View Figures

View References

1	Li L, Gao Y, Zhang L, Zeng J, He D and Sun Y: Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett. 272:61–69. 2008. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
3	Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 80:1198–1220. 1997. View Article : Google Scholar : PubMed/NCBI
4	Rabinovitch RA, Zelefsky MJ, Gaynor JJ and Fuks Z: Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. 12:206–212. 1994.PubMed/NCBI
5	Baaten G, Voogd AC and Wagstaff J: A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur J Cancer. 40:1127–1144. 2004. View Article : Google Scholar : PubMed/NCBI
6	Zhan HL, Gao X, Zhou XF, Pu XY and Wang DJ: Presence of tumour-infiltrating FOXP3⁺ lymphocytes correlates with immature tumour angiogenesis in renal cell carcinomas. Asian Pac J Cancer Prev. 13:867–872. 2012.PubMed/NCBI
7	Abe H and Kamai T: Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol. 20:944–955. 2013.PubMed/NCBI
8	Witters LA: The blooming of the French lilac. J Clin Invest. 108:1105–1107. 2001. View Article : Google Scholar : PubMed/NCBI
9	Ruiter R, Visser LE, van Herk-Sukel MP, et al: Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 35:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar
11	Wu N, Gu C, Gu H, Hu H, Han Y and Li Q: Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma. 58:482–490. 2011. View Article : Google Scholar : PubMed/NCBI
12	Storozhuk Y, Hopmans SN, Sanli T, et al: Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 108:2021–2032. 2013. View Article : Google Scholar : PubMed/NCBI
13	Fang Z, Tang Y, Fang J, et al: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PloS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
14	Fang Z, Tang Y, Jiao W, et al: Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway. Food Chem Toxicol. 60:246–251. 2013. View Article : Google Scholar : PubMed/NCBI
15	Pollak M: Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
16	Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ben Sahra I, Le Marchand-Brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
18	Xiong Y, Lu QJ, Zhao J and Wu GY: Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev. 13:3275–3279. 2012. View Article : Google Scholar : PubMed/NCBI
19	Goodwin PJ, Ligibel JA and Stambolic V: Metformin in breast cancer: time for action. J Clin Oncol. 27:3271–3273. 2009. View Article : Google Scholar : PubMed/NCBI
20	Okoshi R, Ozaki T, Yamamoto H, et al: Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem. 283:3979–3987. 2008. View Article : Google Scholar : PubMed/NCBI
21	Chen MB, Wu XY, Gu JH, Guo QT, Shen WX and Lu PH: Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys. 60:311–322. 2011. View Article : Google Scholar : PubMed/NCBI
22	Liu J, Li M, Song B, et al: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 31:264–270. 2013. View Article : Google Scholar : PubMed/NCBI
23	Senderowicz AM: Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol. 16:670–678. 2004. View Article : Google Scholar : PubMed/NCBI
24	Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
25	Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
26	Song E, Ma X, Li H, et al: Attenuation of krüppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma. PloS One. 8:e677582013.
27	Laviolette LA, Wilson J, Koller J, et al: Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PloS One. 8:e667752013. View Article : Google Scholar
28	Circu ML and Aw TY: Glutathione and modulation of cell apoptosis. Biochim Biophys Acta. 1823:1767–1777. 2012. View Article : Google Scholar : PubMed/NCBI
29	Andersen JL and Kornbluth S: The tangled circuitry of metabolism and apoptosis. Mol Cell. 49:399–410. 2013. View Article : Google Scholar : PubMed/NCBI
30	Petsophonsakul P, Pompimon W and Banjerdpongchai R: Apoptosis induction in human leukemic promyelocytic HL-60 and monocytic U937 cell lines by goniothalamin. Asian Pac J Cancer Prev. 14:2885–2889. 2013. View Article : Google Scholar : PubMed/NCBI
31	Smith MA and Schnellmann RG: Calpains, mitochondria, and apoptosis. Cardiovasc Res. 96:32–37. 2012. View Article : Google Scholar : PubMed/NCBI
32	Czabotar PE, Lessene G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
33	Hasan TN, BLG, Shafi G, Al-Hazzani AA and Alshatwi AA: Anti-proliferative effects of organic extracts from root bark of Juglans Regia L (RBJR) on MDA-MB-231 human breast cancer cells: role of Bcl-2/Bax, caspases and Tp53. Asian Pac J Cancer Prev. 12:525–530. 2011.PubMed/NCBI
34	Zhang N, Kong X, Yan S, Yuan C and Yang Q: Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci. 101:2375–2383. 2010. View Article : Google Scholar : PubMed/NCBI
35	Zhang N, Wang X, Huo Q, et al: The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in breast cancer. J Biol Chem. 288:9396–9407. 2013. View Article : Google Scholar
36	Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nature Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
37	Himelstein BP, Lee EJ, Sato H, Seiki M and Muschel RJ: Tumor cell contact mediated transcriptional activation of the fibroblast matrix metalloproteinase-9 gene: involvement of multiple transcription factors including Ets and an alternating purine-pyrimidine repeat. Clin Exp Metastasis. 16:169–177. 1998. View Article : Google Scholar
38	Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.PubMed/NCBI
39	Hu Y and Ivashkiv LB: Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J Immunol. 176:6022–6033. 2006. View Article : Google Scholar : PubMed/NCBI
40	Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI